Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Clin. transl. oncol. (Print) ; 18(11): 1082-1087, nov. 2016. tab, graf
Article in English | IBECS | ID: ibc-156873

ABSTRACT

Bevacizumab is a monoclonal antibody which is a vascular endothelial growth factor inhibitor. It obscures vascularization of tumor tissue and damages intratumoral microcirculation. The damaged intratumoral microcirculation leads to tissue hypoxia and results in increase of uric acid level. The main aim of our study was to investigate the relationship between uric acid change and response to bevacizumab therapy. This study included a total of 158 patients with metastatic colorectal cancer who had received bevacizumab therapy. The number of male patients was 100 (63.3 %) while female patients number was 58 (37.7 %). The median age was 61 (29-83). There was relationship between increase of uric acid level of third month uric acid level and stable disease (p < 0.001). There was a significant overall survival increased in the group with increased uric acid level (p < 0.001). The decline of CEA level was related to uric acid level (p < 0.022). In conclusion, this study is the first showing significant increases of serum uric acid in patients with metastatic colorectal cancer who favorably responded to chemotherapy with bevacizumab. But further studies are justified to test whether monitoring uric acid levels might predict clinical outcomes of patients with metastatic colorectal cancer (AU)


No disponible


Subject(s)
Humans , Male , Female , Colonic Neoplasms/diagnosis , Colonic Neoplasms/drug therapy , Colonic Neoplasms/immunology , Bevacizumab/therapeutic use , Neoplasm Metastasis/diagnosis , Neoplasm Metastasis/drug therapy , Neoplasm Metastasis/pathology , Uric Acid/analysis , Uric Acid/blood , Antibodies, Monoclonal/analysis , Cohort Studies , 28599
2.
3.
Clin Transl Oncol ; 18(11): 1082-1087, 2016 Nov.
Article in English | MEDLINE | ID: mdl-26781472

ABSTRACT

Bevacizumab is a monoclonal antibody which is a vascular endothelial growth factor inhibitor. It obscures vascularization of tumor tissue and damages intratumoral microcirculation. The damaged intratumoral microcirculation leads to tissue hypoxia and results in increase of uric acid level. The main aim of our study was to investigate the relationship between uric acid change and response to bevacizumab therapy. This study included a total of 158 patients with metastatic colorectal cancer who had received bevacizumab therapy. The number of male patients was 100 (63.3 %) while female patients number was 58 (37.7 %). The median age was 61 (29-83). There was relationship between increase of uric acid level of third month uric acid level and stable disease (p < 0.001). There was a significant overall survival increased in the group with increased uric acid level (p < 0.001). The decline of CEA level was related to uric acid level (p < 0.022). In conclusion, this study is the first showing significant increases of serum uric acid in patients with metastatic colorectal cancer who favorably responded to chemotherapy with bevacizumab. But further studies are justified to test whether monitoring uric acid levels might predict clinical outcomes of patients with metastatic colorectal cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bevacizumab/therapeutic use , Biomarkers, Tumor/blood , Colonic Neoplasms/pathology , Uric Acid/blood , Adult , Aged , Aged, 80 and over , Cohort Studies , Colonic Neoplasms/blood , Colonic Neoplasms/drug therapy , Female , Humans , Male , Middle Aged , Neoplasm Metastasis
4.
Indian J Nephrol ; 25(4): 251-4, 2015.
Article in English | MEDLINE | ID: mdl-26199480

ABSTRACT

Spontaneous retroperitoneal hemorrhage (SRH) is a rare and potentially fatal condition. Acquired cystic kidney disease (ACKD) may cause SRH in hemodialysis patients. However, presentation of retroperitoneal hematoma as hemoperitoneum in peritoneal dialysis (PD) patients is exceedingly rare. We report a 44-year-old male PD patient who presented with hemoperitoneum secondary to retroperitoneal hematoma. The reason of SRH was rupture of the cysts of ACKD. The patient underwent unilateral nephrectomy with subsequent disappearance of hemoperitoneum. The importance of this case lies in the fact that the patients who have been receiving dialysis for a long time should be under surveillance in terms of ACKD development and potential associated complications such as cyst hemorrhage and malignancy.

5.
Exp Clin Endocrinol Diabetes ; 123(5): 267-71, 2015 May.
Article in English | MEDLINE | ID: mdl-25853704

ABSTRACT

BACKGROUND: Type 2 Diabetes Mellitus is a leading cause of end stage renal disease in the worldwide. Inflammation is regarded as one of the main reasons for the progression of diabetes complications. We aimed to evaluate the association of neutrophil to lymphocyte ratio (NLR) as indicator of systemic inflammation with diabetic retinopathy and nephropathy. PATIENTS AND METHODS: This is a cross-sectional study of 114 prevalent type 2 diabetic subjects. All of the patients underwent detailed examination for the presence of diabetic retinopathy and nephropathy. Diabetic retinopathy was approved and classified according to findings based on flouresceint fundal angiography results. Estimated glomerular filtration rate (eGFR) and microalbumin to creatinine ratio were calculated to establish the diabetic nephropathy. NLR was calculated as ratio of absolute neutrophil count to absolute lymphocyte count. RESULTS: Retinopathy was present in 55 (48.2%) out of 114 patients, whereas nephropathy was present in 62 patients (54.3%). NLR was significantly higher in patients with nephropathy than in patients without nephropathy. NLR was also positively correlated with CRP (p=0.017, r=0.224) and microalbuminuria (p=0.016, r=0.257) whereas negatively correlated with eGFR (p<0.001, r=-0.337) values in the whole cohort. NLR was independent predictors for diabetic nephropathy, whereas it did not appear as an independent associate of diabetic retinopathy. CONCLUSION: NLR and diabetic nephropathy have an independent association between them whereas there was no independent association between NLR with retinopathy in type 2 diabetic patients.


Subject(s)
Diabetes Mellitus, Type 2/complications , Diabetic Angiopathies/immunology , Diabetic Nephropathies/immunology , Lymphocytes/immunology , Neutrophils/immunology , Adult , Aged , Aged, 80 and over , Algorithms , Cohort Studies , Cross-Sectional Studies , Diabetic Angiopathies/blood , Diabetic Angiopathies/epidemiology , Diabetic Angiopathies/physiopathology , Diabetic Nephropathies/blood , Diabetic Nephropathies/epidemiology , Diabetic Nephropathies/physiopathology , Diabetic Retinopathy/diagnosis , Diabetic Retinopathy/epidemiology , Diabetic Retinopathy/immunology , Diabetic Retinopathy/physiopathology , Female , Fluorescein Angiography , Glomerular Filtration Rate , Hospitals, Community , Humans , Inflammation/blood , Inflammation/epidemiology , Inflammation/physiopathology , Male , Middle Aged , Outpatient Clinics, Hospital , Severity of Illness Index , Turkey/epidemiology
7.
Transpl Infect Dis ; 13(6): 638-40, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21504527

ABSTRACT

Urinary tract infection (UTI) is common in renal transplant recipients and may worsen allograft and patient survival. Many risk factors such as age, female gender, immunosuppression, comorbidity, deceased-donor kidney transplantation, and uretheral catheterization are involved in development of UTI. Acinetobacter baumannii has rarely been reported as a causative agent for development of UTI. Here, we present an unusual case of a renal transplant recipient who developed community-acquired carbapenem-resistent A. baumannii UTI.


Subject(s)
Acinetobacter Infections/drug therapy , Acinetobacter baumannii/isolation & purification , Community-Acquired Infections/drug therapy , Kidney Transplantation , Postoperative Complications , Acinetobacter Infections/etiology , Adult , Carbapenems , Community-Acquired Infections/etiology , Female , Humans , Marriage , Microbial Sensitivity Tests , Urinary Tract Infections/drug therapy , Urinary Tract Infections/etiology , beta-Lactam Resistance
8.
Int J Impot Res ; 23(1): 27-31, 2011.
Article in English | MEDLINE | ID: mdl-21209618

ABSTRACT

ED is prevalent in hemodialysis (HD) patients, and closely related to poor sleep and depression. Efficacy of treating ED either with sildenafil or vardenafil has been shown to be beneficial in ameliorating concomitant depression in non-HD patients. It is yet to be shown whether treatment of ED with a PDE-5 inhibitor would improve poor sleep in HD patients. We aimed to compare the effects of sildenafil and vardenafil on sleep quality and depression in HD patients with ED. A total of 32 maintenance HD patients with ED randomized into two groups to receive either sildenafil or vardenafil for 4 weeks. After a 2-week washout and a crossover, each group received the other drug for another 4-week period. Sleep quality and depression were evaluated via post-sleep inventory (PSI) and Beck's depression inventory (BDI), respectively, at baseline and at the end of the treatment. Sildenafil and vardenafil both improved PSI and BDI scores significantly compared with pretreatment values. However, there was no difference between sildenafil and vardenafil with respect to these parameters. PDE-5 inhibitors, sildenafil and vardenafil, caused a significant improvement in sleep quality and depression in this cohort of HD patients with ED.


Subject(s)
Depressive Disorder/physiopathology , Erectile Dysfunction/drug therapy , Imidazoles/therapeutic use , Kidney Failure, Chronic/physiopathology , Phosphodiesterase 5 Inhibitors/therapeutic use , Piperazines/therapeutic use , Sleep/drug effects , Sulfones/therapeutic use , Adult , Cross-Over Studies , Depressive Disorder/complications , Depressive Disorder/psychology , Erectile Dysfunction/complications , Erectile Dysfunction/physiopathology , Erectile Dysfunction/psychology , Humans , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/psychology , Male , Middle Aged , Prospective Studies , Purines/therapeutic use , Renal Dialysis , Self Report , Sildenafil Citrate , Surveys and Questionnaires , Treatment Outcome , Triazines/therapeutic use , Vardenafil Dihydrochloride
9.
Transpl Infect Dis ; 13(2): 178-81, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20738834

ABSTRACT

Fungal pathogens are increasingly encountered after renal transplantation. Aspergillus causes significant morbidity and mortality in transplant patients. Fungal thyroiditis is a rare occurrence owing to unique features of the thyroid gland. Most cases are caused by Aspergillus species and have been described in immunocompromised patients. Presentation may be identical with that of subacute thyroiditis, in which hyperthyroidism features and painful thyroid are the prominent findings. Diagnosis can be ascertained by fine-needle aspiration of thyroid showing branching hyphae of Aspergillus. We describe a renal transplant patient who developed Aspergillus thyroiditis as part of a disseminated infection successfully treated with voriconazole.


Subject(s)
Aspergillosis/etiology , Kidney Transplantation/adverse effects , Thyroiditis/microbiology , Antifungal Agents/administration & dosage , Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillosis/pathology , Caspofungin , Echinocandins/administration & dosage , Echinocandins/therapeutic use , Humans , Lipopeptides , Pyrimidines/administration & dosage , Pyrimidines/therapeutic use , Thyroid Gland/microbiology , Thyroiditis/drug therapy , Thyroiditis/pathology , Triazoles/administration & dosage , Triazoles/therapeutic use , Voriconazole
10.
Transplant Proc ; 42(7): 2813-5, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20832595

ABSTRACT

The incidence of cancer is greater in transplant recipients compared with the general population. Posttransplantation lymphoproliferative disorder (PTLD) is the second most common cancer in these patients. Non-Hodgkin lymphoma is most commonly observed, and multiple myeloma (PTLD-MM) accounts for less than 4% of PTLDs. Most reported PTLD-MM is of recipient origin, and to date, few cases of donor-origin PTLD-MM have been reported. Bortezomib is a protease inhibitor that has been used successfully to treat multiple myeloma. Herein, we describe the case of a patient in whom multiple myeloma developed shortly after paid living-unrelated renal transplantation performed abroad (in Egypt). The patient had no apparent risk factors for PTLD-MM. Thus, it was supposed that PTLD-MM was of donor origin, considering its early development, lack of recipient risk factors, and no available donor medical status. To our knowledge, this report is the first to describe the use of bortezomib in this setting. Although bortezomib plus dexamethasone therapy resulted in hematologic remission, the patient remained dialysis-dependent.


Subject(s)
Kidney Transplantation/adverse effects , Kidney Transplantation/economics , Multiple Myeloma/etiology , Transplantation/economics , Egypt , Humans , Kidney Transplantation/standards , Lymphoproliferative Disorders/etiology , Male , Middle Aged , Tissue Donors/classification
11.
Perit Dial Int ; 30(1): 114-6, 2010.
Article in English | MEDLINE | ID: mdl-20056993

ABSTRACT

Chronic kidney disease and need for renal replacement therapy in hemophiliacs are relatively rare occurrences. Successful hemodialysis and peritoneal dialysis applications have been reported in the literature. We report a difficult-to-manage patient with hemophilia A plus factor VIII inhibitor who presented with gastrointestinal bleeding complicated by uremia. We admitted this hemophilia A patient with gastrointestinal bleeding who did not take regular factor infusions. He also had chronic kidney disease due to urinary stone disease. Since uremia might have contributed to bleeding, we chose hemodialysis along with factor VIII supplementation. His factor VIII and factor VIII inhibitor levels were 4% and 5 Bethesda units respectively. In order to bypass the inhibitor, we applied factor VIIA and prothrombin complex concentrate. After cessation of the hemorrhage, we placed a Tenckhoff catheter under prothrombin complex concentrate infusion. We did not observe any perioperative complication. To our knowledge, this is the first report of successful peritoneal dialysis in a hemophilia A patient who had factor VIII inhibitors.


Subject(s)
Factor VIII/immunology , Hemophilia A/complications , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Peritoneal Dialysis , Hemophilia A/immunology , Humans , Kidney Failure, Chronic/immunology , Male , Middle Aged
12.
Perit Dial Int ; 30(1): 119-21, 2010.
Article in English | MEDLINE | ID: mdl-20056997

ABSTRACT

Morganella morganii, a gram-negative bacillus, is a rare cause of peritonitis. In this article we report a 55-year-old female patient with peritonitis due to Morganella morganii who was receiving continuous ambulatory peritoneal dialysis (CAPD).


Subject(s)
Enterobacteriaceae Infections , Morganella morganii , Peritoneal Dialysis, Continuous Ambulatory/adverse effects , Peritonitis/microbiology , Female , Humans , Middle Aged
14.
J Exp Clin Cancer Res ; 23(2): 343-4, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15354421

ABSTRACT

Malignant thymomas are associated with numerous autoimmune disorders including myasthenia gravis. Myastenia gravis is characterized by antibodies against the acetylcholine receptors located on the neuromuscular junction of the skeletal muscle. We present a case with malignant thymoma who developed myasthenia crisis while he was treated with cisplatin chemotherapy.


Subject(s)
Antineoplastic Agents/adverse effects , Cisplatin/adverse effects , Myasthenia Gravis/chemically induced , Neuromuscular Junction/immunology , Thymoma/drug therapy , Thymus Neoplasms/drug therapy , Child, Preschool , Humans , Male , Muscle, Skeletal/drug effects , Myasthenia Gravis/pathology , Neuromuscular Junction/physiopathology , Receptors, Cholinergic/immunology , Receptors, Cholinergic/metabolism , Thymoma/complications , Thymoma/immunology , Thymus Neoplasms/complications , Thymus Neoplasms/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...